Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD

Exclusion Criteria

• •Lack of informed consent
• •Pregnant and lactating females
• •Acute moderate-severe exacerbation of COPD, acute respiratory failure (pH \< 7,35 and/ or respiratory rate \> 30/min within 3 months prior to inclusion)
• •Unstable heart failure or planned change in medication (hospitalization due to CHF within 3 months prior to inclusion), any angina pectoris
• •Not symptomatic
• •Patient has been committed to an institution by legal or regulatory order
• •Participation in a parallel interventional clinical trial
• •Any COPD maintenance therapy before start of randomization
• •History or diagnosis of Asthma
• •LVEF \<35 % or ICD or pacemaker
• •Myocardial infarction 6 months prior inclusion
• •History of life-threatening arrhythmias (e.g. NSVT or ventricular tachycardia, aFib, AV-Block, pacemaker treatment etc.)
• •History of diagnosis of Thyrotoxicosis
• •Chronic kidney disease with an crea-clearance ≤30 ml/min
• •History of significant alcohol or drug abuse, as judged by the Investigator
• •Fibrotic lung disease (e.g. IPF, ILD)
• •Contraindications for MRT (e.g. pacemaker, defibrillator, ferromagnetic metal implants, tattoos, claustrophobia, etc. according to MRI checklist used in the clinical routine)